New oral gel for tough cancers enters first human tests
NCT ID NCT06143774
Summary
This is the first study to test a new oral gel called TRX-920 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find the highest safe dose, understand the drug's side effects, and see if it helps control the cancer. The gel contains SN38, the active part of a known chemotherapy drug, but in a new form that may work differently.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Medical University Hospital
RECRUITINGTaichung, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cheng-Kung University Hospital
RECRUITINGTainan, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Taipei Medical University Hospital
RECRUITINGTaipei, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.